Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB
Gespeichert in:
| Veröffentlicht in: | The FASEB journal 2001-07, Vol.15 (9), p.1622-1624 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1624 |
|---|---|
| container_issue | 9 |
| container_start_page | 1622 |
| container_title | The FASEB journal |
| container_volume | 15 |
| creator | Niederberger, E Tegeder, I Vetter, G Schmidtko, A Schmidt, H Euchenhofer, C Bräutigam, L Grösch, S Geisslinger, G |
| description | |
| doi_str_mv | 10.1096/fj.00-0716fje |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70965434</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70965434</sourcerecordid><originalsourceid>FETCH-LOGICAL-p122t-41bc4ff20bed7fc752326bd2033090e51293275507096375cebb61567665e7413</originalsourceid><addsrcrecordid>eNo1kDFPwzAUhD2AaCmMrMgTm8uzHdvNCBUFpAoW2JAix7GpSxKH2EHtvydAmU4nfXd67xC6oDCnkMtrt50DEFBUuq09QlNY5IxIyRcTdBrjFgAoUHmCJpRmTAmQU_S2tLU1YedLXIdoI_YpYt0mT3zrat00OoV-j61z3mizxzrhjX_f4OoXTps-DKPTJvkvnXxocXD4aUU-dNfp2zN07HQd7flBZ-h1dfeyfCDr5_vH5c2adJSxRDJamsw5BqWtlDNKMM5kWTHgHHKwgrKcj-cKUOOTXAljy1JSIZWUwqqM8hm6-uvt-vA52JiKxkdj61q3Ngyx-MmJjGcjeHkAh7KxVdH1vtH9vvjfg38DrixflQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70965434</pqid></control><display><type>article</type><title>Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Niederberger, E ; Tegeder, I ; Vetter, G ; Schmidtko, A ; Schmidt, H ; Euchenhofer, C ; Bräutigam, L ; Grösch, S ; Geisslinger, G</creator><creatorcontrib>Niederberger, E ; Tegeder, I ; Vetter, G ; Schmidtko, A ; Schmidt, H ; Euchenhofer, C ; Bräutigam, L ; Grösch, S ; Geisslinger, G</creatorcontrib><identifier>ISSN: 0892-6638</identifier><identifier>DOI: 10.1096/fj.00-0716fje</identifier><identifier>PMID: 11427506</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Celecoxib ; Cyclooxygenase 2 ; Dinoprostone - metabolism ; Disease Models, Animal ; Inflammation - chemically induced ; Inflammation - drug therapy ; Interleukin-1 - metabolism ; Isoenzymes - genetics ; Isoenzymes - metabolism ; Male ; NF-kappa B - metabolism ; Prostaglandin-Endoperoxide Synthases - genetics ; Prostaglandin-Endoperoxide Synthases - metabolism ; Pyrazoles ; Rats ; Rats, Sprague-Dawley ; Sulfonamides - administration & dosage ; Sulfonamides - pharmacology ; Sulfonamides - therapeutic use ; Transcription, Genetic - drug effects ; Tumor Necrosis Factor-alpha - metabolism ; Zymosan</subject><ispartof>The FASEB journal, 2001-07, Vol.15 (9), p.1622-1624</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11427506$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Niederberger, E</creatorcontrib><creatorcontrib>Tegeder, I</creatorcontrib><creatorcontrib>Vetter, G</creatorcontrib><creatorcontrib>Schmidtko, A</creatorcontrib><creatorcontrib>Schmidt, H</creatorcontrib><creatorcontrib>Euchenhofer, C</creatorcontrib><creatorcontrib>Bräutigam, L</creatorcontrib><creatorcontrib>Grösch, S</creatorcontrib><creatorcontrib>Geisslinger, G</creatorcontrib><title>Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><subject>Animals</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Celecoxib</subject><subject>Cyclooxygenase 2</subject><subject>Dinoprostone - metabolism</subject><subject>Disease Models, Animal</subject><subject>Inflammation - chemically induced</subject><subject>Inflammation - drug therapy</subject><subject>Interleukin-1 - metabolism</subject><subject>Isoenzymes - genetics</subject><subject>Isoenzymes - metabolism</subject><subject>Male</subject><subject>NF-kappa B - metabolism</subject><subject>Prostaglandin-Endoperoxide Synthases - genetics</subject><subject>Prostaglandin-Endoperoxide Synthases - metabolism</subject><subject>Pyrazoles</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - pharmacology</subject><subject>Sulfonamides - therapeutic use</subject><subject>Transcription, Genetic - drug effects</subject><subject>Tumor Necrosis Factor-alpha - metabolism</subject><subject>Zymosan</subject><issn>0892-6638</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kDFPwzAUhD2AaCmMrMgTm8uzHdvNCBUFpAoW2JAix7GpSxKH2EHtvydAmU4nfXd67xC6oDCnkMtrt50DEFBUuq09QlNY5IxIyRcTdBrjFgAoUHmCJpRmTAmQU_S2tLU1YedLXIdoI_YpYt0mT3zrat00OoV-j61z3mizxzrhjX_f4OoXTps-DKPTJvkvnXxocXD4aUU-dNfp2zN07HQd7flBZ-h1dfeyfCDr5_vH5c2adJSxRDJamsw5BqWtlDNKMM5kWTHgHHKwgrKcj-cKUOOTXAljy1JSIZWUwqqM8hm6-uvt-vA52JiKxkdj61q3Ngyx-MmJjGcjeHkAh7KxVdH1vtH9vvjfg38DrixflQ</recordid><startdate>200107</startdate><enddate>200107</enddate><creator>Niederberger, E</creator><creator>Tegeder, I</creator><creator>Vetter, G</creator><creator>Schmidtko, A</creator><creator>Schmidt, H</creator><creator>Euchenhofer, C</creator><creator>Bräutigam, L</creator><creator>Grösch, S</creator><creator>Geisslinger, G</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200107</creationdate><title>Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB</title><author>Niederberger, E ; Tegeder, I ; Vetter, G ; Schmidtko, A ; Schmidt, H ; Euchenhofer, C ; Bräutigam, L ; Grösch, S ; Geisslinger, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p122t-41bc4ff20bed7fc752326bd2033090e51293275507096375cebb61567665e7413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Animals</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Celecoxib</topic><topic>Cyclooxygenase 2</topic><topic>Dinoprostone - metabolism</topic><topic>Disease Models, Animal</topic><topic>Inflammation - chemically induced</topic><topic>Inflammation - drug therapy</topic><topic>Interleukin-1 - metabolism</topic><topic>Isoenzymes - genetics</topic><topic>Isoenzymes - metabolism</topic><topic>Male</topic><topic>NF-kappa B - metabolism</topic><topic>Prostaglandin-Endoperoxide Synthases - genetics</topic><topic>Prostaglandin-Endoperoxide Synthases - metabolism</topic><topic>Pyrazoles</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - pharmacology</topic><topic>Sulfonamides - therapeutic use</topic><topic>Transcription, Genetic - drug effects</topic><topic>Tumor Necrosis Factor-alpha - metabolism</topic><topic>Zymosan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Niederberger, E</creatorcontrib><creatorcontrib>Tegeder, I</creatorcontrib><creatorcontrib>Vetter, G</creatorcontrib><creatorcontrib>Schmidtko, A</creatorcontrib><creatorcontrib>Schmidt, H</creatorcontrib><creatorcontrib>Euchenhofer, C</creatorcontrib><creatorcontrib>Bräutigam, L</creatorcontrib><creatorcontrib>Grösch, S</creatorcontrib><creatorcontrib>Geisslinger, G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Niederberger, E</au><au>Tegeder, I</au><au>Vetter, G</au><au>Schmidtko, A</au><au>Schmidt, H</au><au>Euchenhofer, C</au><au>Bräutigam, L</au><au>Grösch, S</au><au>Geisslinger, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2001-07</date><risdate>2001</risdate><volume>15</volume><issue>9</issue><spage>1622</spage><epage>1624</epage><pages>1622-1624</pages><issn>0892-6638</issn><cop>United States</cop><pmid>11427506</pmid><doi>10.1096/fj.00-0716fje</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0892-6638 |
| ispartof | The FASEB journal, 2001-07, Vol.15 (9), p.1622-1624 |
| issn | 0892-6638 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70965434 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Animals Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - pharmacology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Celecoxib Cyclooxygenase 2 Dinoprostone - metabolism Disease Models, Animal Inflammation - chemically induced Inflammation - drug therapy Interleukin-1 - metabolism Isoenzymes - genetics Isoenzymes - metabolism Male NF-kappa B - metabolism Prostaglandin-Endoperoxide Synthases - genetics Prostaglandin-Endoperoxide Synthases - metabolism Pyrazoles Rats Rats, Sprague-Dawley Sulfonamides - administration & dosage Sulfonamides - pharmacology Sulfonamides - therapeutic use Transcription, Genetic - drug effects Tumor Necrosis Factor-alpha - metabolism Zymosan |
| title | Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A16%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Celecoxib%20loses%20its%20anti-inflammatory%20efficacy%20at%20high%20doses%20through%20activation%20of%20NF-kappaB&rft.jtitle=The%20FASEB%20journal&rft.au=Niederberger,%20E&rft.date=2001-07&rft.volume=15&rft.issue=9&rft.spage=1622&rft.epage=1624&rft.pages=1622-1624&rft.issn=0892-6638&rft_id=info:doi/10.1096/fj.00-0716fje&rft_dat=%3Cproquest_pubme%3E70965434%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70965434&rft_id=info:pmid/11427506&rfr_iscdi=true |